CN106924271A - Ginseng saponin C-K is used to prepare treatment psoriasis - Google Patents
Ginseng saponin C-K is used to prepare treatment psoriasis Download PDFInfo
- Publication number
- CN106924271A CN106924271A CN201511029119.2A CN201511029119A CN106924271A CN 106924271 A CN106924271 A CN 106924271A CN 201511029119 A CN201511029119 A CN 201511029119A CN 106924271 A CN106924271 A CN 106924271A
- Authority
- CN
- China
- Prior art keywords
- ginseng saponin
- psoriasis
- pharmaceutical composition
- pharmaceutically acceptable
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides the purposes of ginseng saponin C-K and its pharmaceutically acceptable solvate or hydrate in the medicine for being used for treating psoriasis is prepared, the medicine box containing the ginseng saponin C-K, pharmaceutical composition for treating psoriasis, and the method for preparing described pharmaceutical composition.
Description
Technical field：
The invention provides the purposes of ginseng saponin C-K and its pharmaceutically acceptable solvate or hydrate in the medicine for being used for treating psoriasis is prepared, the medicine box containing the ginseng saponin C-K, pharmaceutical composition for treating psoriasis, and the method for preparing described pharmaceutical composition.
Background technology：
" psoriasis ", is a kind of edge clear, erythema, pachyderma, the scaly chronic, recurrent of surface covering, dermal inflammatory disease also known as psoriasis；Obstinate, easily recurrence.Psoriasis can fall ill in entire patient, and stretch side in scalp, four limbs and back is relatively conventional.Clinical symptoms are shown as patient and erythema occur, occur the dry scales of skin that peel off in erythema repeatedly, and the scales of skin that peel off occurs blutpunkte after coming off.
Psoriasis is widely different in the incidence of disease all over the world, America Andes American Indian and Australia Original Resident incidence of disease are 0%, and Northern Europe and the Russian part population incidence of disease are 11%, there is 2.2-2.6% people to suffer from the disease in the U.S., China still lacks accurate statistics, at present it has been reported that being 0.2-1.5%.Whole world total incidence is about 3%.Because life quality in patients with psoriasis is severely impacted, or even employment and income are also a problem.
Skin is to prevent invader or damage anti-satellite line foremost, it is made up of many epitheliums and immunizing composition, and these immunizing compositions constitute the related lymphoid tissue (SALT) of skin, under pathologic condition or environmental stimuli is strong or chronic repetitious stimulation, or due to body genetic defect, abnormal response will be produced.Common psoriasis pustulosa is that understanding is relatively clear at present and the skin chronic inflammation disease mediated by T cell and BMDC approved for everybody.
Research has shown that psoriasis is not only to be influenceed by gene, but it is also related to environmental factor, the known environmental factor that can cause onset of psoriasis have infection, stress, obesity, some medicines, smoking, excessive drinking, or even weather, weather can induce with a part of patient or aggravate the state of an illness.
Above-mentioned factors form the typical pathological change of psoriatic's skin, Keratinocyte Proliferation accelerates to cause pachyderma, epithelial cells normal differentiation process can not occur, normal stratum granulosum is lost, nucleus still retains keratin in surface epithelium, all there are 16 type keratin in whole epidermis, skin corium has substantial amounts of keratin.Neutrophil accumulation has substantial amounts of monocyte, the mainly BMDC in marrow source and T cell in epidermis in corium, and the erythema of psoriatic's local skin is due to the substantial amounts of skin heart expanded.
The medicine of conventional treatment psoriasis can be divided into whole body system medication and local externally applied drug at present, in general in, severe psoriatic is frequently with systemic administration, and slight or part moderate patient is frequently with external used medicine whole body system medication, most clinicians are accustomed to methopterin (MTX), for the First Line whole body therapeutic psoriasis or psoriasis arthropathica of psoriatic, and another conventional medicine is cyclosporin A, because it can be by preventing the expression of T cell activation and cell factor.The two medicines are almost into the goldstandard of curing psoriasis medicine, but such medicine, and due to belonging to cell toxicant kind anti-cancer drugs or immunodepressant originally, prolonged application will necessarily produce serious toxic and side effect.
In recent years due to the joint efforts of many researchers and clinician, biological agent and oral general targeting small-molecule drug of many new treatments etc. is occurred in that.Wherein protruded the most with TNF antagonists, the biological products such as such as Etanercept and anti-TNF antibodies aldalimumab, infliximab bring Gospel to medium and heavy psoriatic；New oral antipsoriatic small-molecule drug is for example：The inhibitor apremilast of dimethyl fumarate (dimethyl fumarate) and 4 type phosphodiesterases, the release (such as IL-12, IL-23 and TNF) of pro-inflammatory cytokine, the generation of induction anti-inflammatory cytokines (such as IL-10) can be reduced.
Clinically Tofacitinib can be used for moderate and severe psoriatic as oral formulations.
Patient for slight psoriatic, i.e. skin damaged area less than 10%, generally using local external use's administration.For middle severe patient, while using ultraviolet light and whole body therapeutic, externally applied drug can also be used as auxiliary treatment.Current psoriasis local application has：
Glucocorticoids：It is the most-often used external preparation of current psoriatic, varying strength and formulation can be selected according to the progress of skin damaged size position and the state of an illness.Glucocorticoid medicine can produce anti-inflammatory, antiproliferative, immunosupress and vasoconstrictive effect and treat psoriasis, but local use can cause glucocorticoid to produce side effect, and long-term use can produce tolerance, and knock-on can be produced after drug withdrawal.
Vitamin D 3 analogs：Its representative drugs is Calcipotriol, is psoriasis externally applied drug conventional at present, and its main effect is combined with vitamin D receptor, it is suppressed that keratinocyte proliferation, and induces it to break up, and is the goldstandard for treating psoriasis at present.The medicine worked compared with glucocorticoid medicine it is slow, but it is longer compared with the glucocorticoids intermittent phase, but the medicine has transient stimulation to skin damaged periphery and gut purge of having blood in stool is transient increases.
RA analog derivative, such as tazarotene.It can stimulate keratinocyte normalization, reduce hyper-proliferative, reduce the expression of Inflammation Marker.The medicine is that local application's curative effect of conventional psoriasis is good, but has stimulation for skin damaged and surrounding area, and the medicine is forbidden to be used in the gestational period, and child patient is used with caution.
Immunodepressant tacrolimus and Elidel, belong to calcium and adjust phosphate, can effectively treat the psoriasis of side facial and in the wrong.The side effect of the medicine is skin irritatin and itch, and FDA has issued the black box report of controversial lymphopathy, so using with caution.
Tar class medicine：This product effectively, can be such that clothes colours and coal tar smell really to some psoriatics, and animal experiment has carcinogenic risk, although failing to confirm in human body.Children should be careful.
Anthraline class：Coloured without coal tar oils niff and clothes.
Salicylic acid：There is certain curative effect, and the contraindication dosage specified without FDA, but large area is used, and particularly hepatic and kidney function obstacle person should be careful.
Said medicine is used in combination or interval is used, but on the premise of must account for their physicochemical property and mechanism of action, may obtain more preferable curative effect.
Invention summary
This application provides a kind of purposes for being used to treat psoriasis with ginseng saponin C-K.Using ginseng saponin C-K treat psoriasis advantage be：
Ginseng saponin C-K has antiinflammatory action, and the effect is all effective for psoriasis and rheumatoid arthritis；
Ginseng saponin C-K can suppress the hyper-proliferative of keratinocyte, and induce it to break up；
Ginseng saponin C-K can suppress blood vessel hyperplasia and expansion；
Ginseng saponin C-K can suppress the aggregation of some inflammatory cells and the release of inflammatory factor；
Ginseng saponin C-K side effect is minimum, even if also being had no side effect under exceeding well over psoriasis topical dose.
Therefore, for the treatment of psoriasis, the inventive method is highly effective and has no side effect.
An invention according to the application, this application provides the purposes of ginseng saponin C-K and its pharmaceutically acceptable solvate or hydrate in the medicine for being used for treating psoriasis is prepared.
According to the preferred embodiment of the application, the psoriasis includes psoriasis vulgaris.
An invention according to the application, this application provides a kind of medicine box, it is characterised in that the medicine box includes ginseng saponin C-K or its pharmaceutically acceptable solvate or hydrate, the medicine box is used to treat psoriasis.
An invention according to the application, this application provides a kind of pharmaceutical composition, it is characterised in that described pharmaceutical composition includes ginseng saponin C-K or its pharmaceutically acceptable solvate or hydrate, and pharmaceutically acceptable carrier, described pharmaceutical composition is for treating psoriasis.
An invention according to the application, this application provides a kind of preparation method of the pharmaceutical composition containing ginseng saponin C-K, it is characterized in that, to mix to prepare with pharmaceutically acceptable carrier according to ginseng saponin C-K or its pharmaceutically acceptable solvate or hydrate, described pharmaceutical composition is used to treat psoriasis.
Brief description of the drawings
The accompanying drawing of the subsidiary herein and part that forms this specification it is exemplary show the present invention, and be further used for illustrating principle of the invention together with specification and those skilled in the relevant art made and the present invention is used.Embodiments of the invention only come that reference will be made to the accompanying drawings as an example.
Fig. 1 and Fig. 2 show the result of the immunohistochemical staining of ginseng saponin C-K and blank for HaCaT cell differentiations；Fig. 1 show using 20 μ g/ml ginseng saponin C-K process 48 hours after, the coloration result of cell；Fig. 2 show 48 hours after blank cell coloration result.
Detailed description of the invention
Definition
" ginsenoside " (Ginsenoside) is a kind of steroid compound triterpenoid saponin, is the active component in ginseng.Ginsenoside has similar basic structure, and basic structure is containing forming four gonane steroids of ring by 30 carbon atom arrangements.Ginsenoside is divided into dammarane type and oleanane type (c-type) in structure.Dammarane type ginsenoside is divided into two class panoxadiol types (A types) and panaxatriol type (Type B) again.The sapogenin of panoxadiol type (A types) and panaxatriol type (Type B) belongs to tetracyclic triterpene, and pier fruit alkane type (c-type) sapogenin belongs to pentacyclic triterpene.
" ginseng saponin C-K " (20 (S)-Ginsenoside C-K), belongs to saponins compound, is diol type (A types) metabolite of ginsenoside in people's enteron aisle.The molecular formula of ginseng saponin C-K is C36H62O8, molecular weight is 622.87, in this application also abbreviation CK.CK molecular structures are shown below：
Ginseng saponin C-K modern study shows that ginseng saponin C-K has the various actives such as anticancer, liver protection, regulation immune system.
Compound described herein includes the anhydride form and non solvate form of the compound, also hydrate and solvate form thereof comprising the compound.Term " solvate " refers to the molecule comprising the compound He one or more pharmaceutically acceptable solvent molecules (such as ethanol) in the application.When wherein solvent is water, the solvate is hydrate.
Term " pharmaceutical composition " represents compound and its pharmaceutically acceptable solvate or hydrate, the mixture with other pharmaceutically acceptable carriers described in one or more containing therapeutically effective amount.It is to be more easily administered to object by the purpose that the compound is prepared into pharmaceutical composition.
Herein described pharmaceutical composition can be tablet, pill, capsule, granule, pulvis, suppository, powder, paste, patch, parenteral solution, solution, suspension, spray, lotion, drops, liniment.
Term " medicine box " in the application, can be with " kit " used interchangeably.This application discloses the therapeutic agent comprising therapeutically effective amount or the medicine box of pharmaceutical composition.According to some implementation methods of the application, the medicine box is also comprising one or more other therapeutic agent.
Term " administration ", can refer to give object by suitable administering mode by the compound or pharmaceutical composition of doses with " giving " or " bestowing " used interchangeably.
" administering mode " includes but is not limited to any administering modes known in the art such as administration in oral administration, intravenous administration, respiratory tract, sublingual administration, local administration, intramuscular adminstration, eye drops, Transdermal absorption, parenteral, Intraperitoneal medication, vagina administration, Buccal administration, per rectum administration.Those skilled in the art should be recognized that the administering mode of object depends on Multiple factors, and the factor is including the composition of the position of disease, the age of object, the order of severity of disease and pharmaceutical composition etc..
Herein described compound or pharmaceutical composition can be administered at any time.Such as described compound or pharmaceutical composition can before object seizure of disease, breaking-out when or breaking-out after be administered.
Herein described compound or pharmaceutical composition can be with single administrations, it is also possible to multiple dosing.When multiple dosing, can be to be spaced random time in the way of.
Herein described compound or pharmaceutical composition can be administered alone, it is also possible to other suitable administered in combination.The administering drug combinations can be for example administered simultaneously with other drugs or consecutive administration.When consecutive administration, can be to be spaced random time in the way of.
The compound of term " effective dose " or " therapeutically effective amount " is directed to object administration metapedes with the amount of the therapeutic effect needed for obtaining.The therapeutic effect such as effective illness for suppressing psoriasis.Those skilled in the art should be recognized that the suitable dosage of the compound depends on Multiple factors, and the factor includes but is not limited to want the body weight for the treatment of target, age and sex, administration time, the order of severity of disease to be treated etc..
Term " treatment " or " treatment " are pointed to after object administration, can be with the disease of " prevention ", " preventing and treating ", " suppression ", " improvement " or " healing " object, disorderly or disease condition.
Term " object ", " subject " or " patient " can be with used interchangeably, and with extensive implication, including people or non-human mammal, such as dog, cat, mouse, rat, sheep, pig, goat, milk cow, non-human primate in the application；Or birds, such as chicken, duck, goose；Including other vertebrates, spinal animal, also including external tissue, prokaryotic or eukaryotic etc..According to some implementation methods of the application, described pair as if mammal.According to some implementation methods of the application, described pair as if primate.According to some implementation methods of the application, described couple as if people.
Term " pharmaceutically acceptable carrier " is pharmaceutically acceptable composition or medium, including but not limited to solvent, excipient, diluent, adjuvant, filler etc..Common pharmaceutically acceptable carrier includes physiological saline, buffer, carbohydrate, gelatin, starch, Ringer's mixture, cellulose etc..The pH of the carrier is usually 3-11, more preferably preferably 5-9,7-8.
Term " half-inhibition concentration (IC50) ", or " semi-inhibit rate ", refer to inhibitor in suppression target substance process, when the activity inhibited of target substance is to half, the concentration of inhibitor.Generally, the rejection ability of inhibitor is stronger, IC50It is lower.According to some implementation methods of the application, the IC of herein described compound50It is the concentration of the compound when 11 β-HSD1 activity inhibiteds 50%.
Unless be otherwise noted in this application or otherwise clearly contradicted, all methods described herein can in any suitable order be carried out according to the understanding of those skilled in the art.
All patents, patent application and the bibliography quoted in the application are incorporated by the application by reference, and its incorporated extent is individually recited as reference just as each document.If the application and provided herein is document between there is conflict, content that should be in the application is defined.
Specific embodiment
This application describes preferred embodiment and embodiment, those skilled in the art can carry out appropriate change on the basis of the application is read to implementation method described herein and embodiment.Therefore, the claimed content of the application includes all equivalent modifications and variations to theme in the application claims in law allowed band.
Embodiment
1
：
CK
External Inhibit proliferaton effect to human epidermal cell
This example demonstrates that ginseng saponin C-K (also referred to herein simply as CK) has the effect of external Inhibit proliferaton to human epidermal cell.In the present embodiment, the CK gives cell by being dissolved in dimethyl sulfoxide, and the human epidermal cell is that people immortalizes epidermal cell (HaCat cells), use MTT (3- (4,5- dimethylthiazoles -2) -2,5- diphenyltetrazolium bromide bromides, trade name：Tetrazolium bromide) method detects the survival and growth of cell.
CK samples (commercially available, Shanghai Standard Biotech Co., Ltd.s purity 92%, Lot3690/20548) are dissolved in dimethyl sulfoxide, the solution that concentration is 10mg/ml is obtained.Make gradient dilution with PBS again, obtain concentration and be respectively 1000 μ g/ml, 100 μ g/ml, 10 μ g/ml, 1 μ g/ml, 0.1 μ g/ml, the dilute sample of 0.01 μ g/ml.By cisplatin for injection (freeze-dried type) (commercially available, Qilu Pharmaceutical Co., Ltd., lot number 1WA2A1411073B) as positive control drug, and it is configured to the concentration for corresponding with a sample.The sample that will have been diluted is added in flat 96 orifice plate, and adds the people of exponential phase to immortalize epidermal cell (HaCat cells, by Shanghai Institute of Pharmaceutical Industry's Secondary Culture), is cultivated 48 hours.Comparative survival rate of cells is detected with mtt assay, and is calculated according to the absorbance value at 492nm and based on below equation.
Table 1：The external growth inhibition effect to HaCat cell lines
| Compound | HaCaT cells IC50 (μ g/ml) |
| CK | ＞ 100 |
| Cis-platinum | 3.12 |
The results show Ginsenoside compound K of table 1 for HaCat cells without obvious CDCC, i.e.,：Without the obvious effect for suppressing HaCat cells propagation.
Embodiment
2
：
CK
Influence to human epidermal cell differentiation
This example demonstrates that the influence that ginseng saponin C-K (CK) breaks up to human epidermal cell.In the present embodiment, the CK gives cell by being dissolved in dimethyl sulfoxide, and the human epidermal cell is that people immortalizes epidermal cell (HaCat cells), and the differentiation of cell is detected using immunohistochemical staining method.
HaCat cell culture in DMEM culture mediums (contain 10%FBS), to 80% blake bottle area when, after 0.25% Trypsin Induced, adjustment cell concentration is 8 × 104/ ml is simultaneously moved into 6 orifice plates (added with sterilized slide in plate) respectively, and Ginsenoside compound K concentration is set to 20 μ g/ml, it is separately added into corresponding hole, and set blank, put in 37 DEG C of cell culture incubators, carry out immunohistochemical staining in the antibody of culture 0h, 48h application anti-keratin 18/19 (being provided by pathological anatomy teaching and research room of The 2nd Army Medical College of PLA) respectively.
As depicted in figs. 1 and 2, Fig. 1 is shown after being processed 48 hours using the ginseng saponin C-K of 20 μ g/ml coloration result, the coloration result of cell；Fig. 2 show 48 hours after blank cell coloration result.As seen from the figure, the HaCat that is processed with ginseng saponin C-K in Fig. 1 is intracellular to there is brown particle, shows that HaCat cell differentiations form keratin, and no keratin is formed in the treatment of the blank of Fig. 2.
Embodiment
3
：
CK
To chicken embryo new vessels
(
Chick chorioallantoic membrane angiogenesis
)
It is inhibited
This example demonstrates that ginseng saponin C-K is inhibited to chicken embryo new vessels (chick chorioallantoic membrane angiogenesis).In the present embodiment, negative controls-BS (abbreviation PBS), positive reference substance-hydrochloric acid Sorafenib (abbreviation Sorafenib), ginseng saponin C-K give chicken embryo respectively.
The operating theater instruments and filter paper that will be used sterilize.Fresh hatching egg is taken, it is continuous under conditions of 37 DEG C, 50% humidity to be incubated 6 days.At the 6th day, whether identification chicken embryo was survived, and the egg for taking out survival is opened a window.Chorioallantoic membrane position first is positioned with illumination, mark is carried out, egg air bag is then pricked into an aperture at one end, the chorioallantoic membrane of egg is placed upward, with the light suction air of rubber pipette bulb, collapse chorioallantoic membrane and separated with eggshell, then open a 1cm above chorioallantoic membrane with blade2Small window.It is 1 μ g/ μ l, the BS (abbreviation PBS) of 2 μ g/ μ l, Sorafenib (4 μ g/ μ l by concentration, DMSO is solvent), ginseng saponin C-K (20 μ g/ μ l, DMSO is solvent) drop on filter paper, air-dry, big blood vessel is avoided, lightly filter paper is placed on chorioallantoic membrane.Small window is sealed with transparent rubberized fabric, continues to be incubated 48 hours, open adhesive tape, window expansion is taken pictures with camera.New vessels is counted according to every branching-point of the blood vessel of photo.Result is as shown in table 2.
Relative inhibition computational methods：
In above-mentioned relative inhibition computing formula, control group is the abbreviation of negative control group (or being PBS groups).
Table 2：The inhibitory action that CK is generated to chicken embryo new vessels
Positive reference substance-Sorafenib is well-known targeting antitumor medicine, there is obvious inhibitory action to blood vessel hyperplasia；The antiangiogenic effect that ginseng saponin C-K is can be seen that by the result of table 2 is also that obviously, its effect is almost suitable with Sorafenib.
Embodiment
4
：
CK
Influence to mouse tail scale epidermal cell
This example demonstrates that ginseng saponin C-K can promote the formation of mouse tail cell granulations layer, and there is doses dependence.
Using 70 mouse, 7 groups, i.e. Normal group, blank emulsifiable paste group, positive control-Calcipotriol group (commercially available, Irish Leo Pharma A/S, product batch number EH8304,15g are randomly divided into：Calcipotriol containing 0.75mg in 0.75mg, i.e. 15g emulsifiable pastes), 0.5%, 1%, 2%, 4% 4 dosage group of tested emulsifiable paste ginseng saponin C-K.Except Normal group, each group animal is used 100 times at the light brush root of the tail 0.5cm of nylon brush before administration, then smears administration (100 μ l) at same position, is administered once daily, successive administration 7 days, and Normal group gives physiological saline.Kill mouse within 1 hour after last time is administered, draw the strip of medicine area skin one, fixed with 10% formalin.FFPE, HE dyeing, observes the tail scale of each mouse under an optical microscope.Scale epidermis between all two follicular orifices has the stratum granulosum person being arranged in rows, and is referred to as the scale for having stratum granulosum, there is the scale number of stratum granulosum in every 100 scales of counting, is as a result represented with percentage.Result is shown in table 3, is checked using t, and calculates the P values for representing conspicuousness statistically.
Table 3：Effect that ginseng saponin C-K is formed to mouse tail scale granular layer of epidermis (n=10,)
Note：Compare with Normal group, P*<0.05,P**<0.01；Compare P# with blank emulsifiable paste group<0.05,P##<0.01.
Table 3 shows, under this experimental condition, compared with Normal group, the administration group successive administration of blank emulsifiable paste group, Calcipotriol group and various dose ginseng saponin C-K emulsifiable paste has stratum granulosum scale number extremely substantially to increase after 7 days.And the administration group of Calcipotriol group and various dose ginseng saponin C-K emulsifiable paste is compared with blank emulsifiable paste group, there is stratum granulosum scale number also extremely substantially to increase.The formation of mouse tail cell granulations layer can be promoted the result shows ginseng saponin C-K emulsifiable paste, and have doses dependence.
Embodiment
5
：
CK
The influence of cavy psoriasis model is induced Propranolol Hydrochloride
Using cavy 70, except Normal group, remaining animal, in ears butt skin, twice daily, continuously smears surrounding with 5% Propranolol Hydrochloride emulsion (about 200 μ l) uniform application, obtains Propranolol Hydrochloride and induces cavy psoriasis model.It is divided into blank emulsifiable paste group, Calcipotriol (ibid) group, 0.5%, 1%, 2%, 4% 4 dosage (ibid) group of tested emulsifiable paste-ginseng saponin C-K after four weeks.Normal group, is normal guinea pig ear, smears physiological saline；Different pharmaceutical (about 200 μ l) is applied to cavy bilateral by other groups hard of hearing, daily 2 times, successive administration 7 days.Animal state is observed during experiment, puts to death cavy within 1 hour after last time is administered.Result is shown in table 4, is checked using t, and calculates the P values for representing conspicuousness statistically.
Table 4：Ginseng saponin C-K Propranolol Hydrochloride is induced cavy psoriasis model be administered 7 days ear's epidermal thickness (N=10)
Note：Variance analysis is carried out using One-Way ANOVA statistical methods, is compared with Normal group, P*<0.05, P**<0.01；Compare P with blank emulsifiable paste group#<0.05, P##<0.01。
Knowable to the epidermal thickness data of table 4, under this experiment condition, blank emulsifiable paste group epidermal thickness is up to 221.65 μm, and with the difference that Normal group has highly significant, it is successful to point out this batch of animal model.Compared with blank emulsifiable paste group, ear's epidermal thickness that each dosage group of ginseng saponin C-K induces Propranolol Hydrochloride the administration 7 days of cavy psoriasis model has obvious inhibitory action.
Claims (5)
1. ginseng saponin C-K or its pharmaceutically acceptable solvate or hydrate are preparing the medicine for treating psoriasis
Purposes in thing.
2. purposes according to claim 1, it is characterised in that the psoriasis includes psoriasis vulgaris.
3. a kind of medicine box, it is characterised in that the medicine box includes ginseng saponin C-K or its pharmaceutically acceptable solvent
Compound or hydrate, the medicine box are used to treat psoriasis.
4. a kind of pharmaceutical composition, it is characterised in that described pharmaceutical composition comprising ginseng saponin C-K or its pharmaceutically
Acceptable solvate or hydrate, and pharmaceutically acceptable carrier, described pharmaceutical composition are used to treat silver-colored bits
Disease.
5. a kind of preparation method of the pharmaceutical composition containing ginseng saponin C-K, it is characterised in that will be according to ginseng soap
Glycosides C-K or its pharmaceutically acceptable solvate or hydrate mix to prepare with pharmaceutically acceptable carrier, institute
Pharmaceutical composition is stated for treating psoriasis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201511029119.2A CN106924271A (en) | 2015-12-31 | 2015-12-31 | Ginseng saponin C-K is used to prepare treatment psoriasis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201511029119.2A CN106924271A (en) | 2015-12-31 | 2015-12-31 | Ginseng saponin C-K is used to prepare treatment psoriasis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106924271A true CN106924271A (en) | 2017-07-07 |
Family
ID=59442215
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201511029119.2A Pending CN106924271A (en) | 2015-12-31 | 2015-12-31 | Ginseng saponin C-K is used to prepare treatment psoriasis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106924271A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108721309A (en) * | 2017-04-19 | 2018-11-02 | 上海医药工业研究院 | Panaxoside CK is used to prepare the application in severe psoriasis vulgaris oral drugs in treatment |
| WO2020061874A1 (en) * | 2018-09-27 | 2020-04-02 | 上海医药工业研究院 | Application of ginsenoside ck in preparation of oral medication for treating moderate-severe psoriasis vulgaris |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101474193A (en) * | 2009-01-14 | 2009-07-08 | 厦门华侨亚热带植物引种园 | Application of ginseng saponin IH901 in preparing angiogenesis inhibitor |
-
2015
- 2015-12-31 CN CN201511029119.2A patent/CN106924271A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101474193A (en) * | 2009-01-14 | 2009-07-08 | 厦门华侨亚热带植物引种园 | Application of ginseng saponin IH901 in preparing angiogenesis inhibitor |
Non-Patent Citations (3)
| Title |
|---|
| YONG-WOOK SHIN ET AL: "Effect of ginsenoside Rb1 and compound K in chronic oxazolone-induced mouse dermatitis", 《INTERNATIONAL IMMUNOPHARMACOLOGY》 * |
| 沈守荣等: "《新编临床医师丛书 常见病处方速查手册 修订版》", 31 August 2014 * |
| 秦川等: "《常见和新发传染病动物模型》", 31 January 2012 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108721309A (en) * | 2017-04-19 | 2018-11-02 | 上海医药工业研究院 | Panaxoside CK is used to prepare the application in severe psoriasis vulgaris oral drugs in treatment |
| WO2020061874A1 (en) * | 2018-09-27 | 2020-04-02 | 上海医药工业研究院 | Application of ginsenoside ck in preparation of oral medication for treating moderate-severe psoriasis vulgaris |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Cui et al. | Extract of Ganoderma lucidum prolongs sleep time in rats | |
| CN102083424B (en) | Methods and use of inducing apoptosis in cancer cells | |
| US20220409671A1 (en) | Composition for preventing or treating ocular diseases comprising amniotic epithelial cell derived exosomes | |
| WO2016082703A1 (en) | Preparation containing chlorogenic acid crystal form and use thereof | |
| WO2016127847A1 (en) | Application of chlorogenic acid in preparing medicines for treating melanoma and medicines for treating melanoma | |
| US20170266219A1 (en) | Pharmaceutical composition comprising gold-containing agent for preventing or treating liver fibrosis or liver cirrhosis | |
| CN106924271A (en) | Ginseng saponin C-K is used to prepare treatment psoriasis | |
| CN110787158A (en) | Application of D609 in preparing medicine for preventing and treating retina injury diseases | |
| CN104906558A (en) | Application of ulinastatin for preparing cervical cancer treatment medicine and pharmaceutical composition | |
| US20210346455A1 (en) | Pharmaceutical composition comprising purple corn extract for prevention or treatment of skin disease | |
| US20190000798A1 (en) | Application of dimethylamino micheliolide | |
| EP2808025B1 (en) | Pharmaceutical composition and quasi-drug cosmetic using same | |
| US20170014354A1 (en) | Zeaxanthin for tumor treatment | |
| Manmuan et al. | Evaluation of standardized extract of Centella Asiatica on cell viability and repressive cancer migration in metastatic colorectal cancer cells in vitro | |
| KR20140032586A (en) | A pharmaceutical composition for radiation therapy of egfr-tki-resistant lung cancer caused by pten function deficiency | |
| CN107296804B (en) | Method for promoting recovery of motor function after spinal cord injury by locally applying beta-elemene | |
| WO2019114676A1 (en) | New medical use of persimmon leaf extract and of preparation of persimmon leaf extract | |
| CN104606177B (en) | Medicinal application of left-handed (R) salbutamol formulation in treatment skin and mucous membrane trauma ulcer | |
| CN108721309A (en) | Panaxoside CK is used to prepare the application in severe psoriasis vulgaris oral drugs in treatment | |
| CN109010350A (en) | Pedunculoside is preparing application and a kind of pharmaceutical composition for treating diabetes skin ulcer in anti-diabetic skin ulcer drug | |
| CN115300507B (en) | Use of I-BRD9 as an ARIH1 agonist | |
| CN113768924B (en) | Composition capable of inhibiting tumor cells and related application thereof | |
| RU2744919C1 (en) | Remedy for the treatment of endometritis in cows | |
| CN106265713A (en) | Cordycepin purposes in the medicine preparing depression and the Fast Anti antidepressant agents being prepared thereof | |
| CN104173354B (en) | Can treating cancer pharmaceutical compositions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170707 |
|
| RJ01 | Rejection of invention patent application after publication |